Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal

Exclusion Criteria

• •1. Seeking treatment for Opioid Use Disorder.
• •2. Current or history of a psychiatric condition that would affect participants' ability to provide informed consent (e.g., mood disorder with functional impairment or schizophrenia) or make participant hazardous for the participant (e.g., recent suicidal ideation) or staff (e.g., significant history of violence).
• •3. Current DSM-V diagnosis of substance use disorders requiring medically managed detoxification, other than OUD (e.g., alcohol or benzodiazepine dependence).
• •4. Medical condition resulting in chronic pain (\>3 months).
• •5. Clinically significant abnormality on physical examination, vital signs, screening laboratory tests, or 12- lead ECG.
• •6. Significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, or neurologic disorder.
• •7. Any surgical, or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the study drugs.
• •8. Baseline hypotension, orthostatic hypotension or syncope, hypertension (blood pressure \> 140/90), pulmonary hypertension or heart disease.
• •9. Any of the following values for laboratory tests:
• •1. positive pregnancy test,
• •2. hemoglobin \< 12 g/dL in males and \< 11 g/dL in females,
• •3. neutrophil count \< 1.0 × 109/L,
• •4. platelet count \< 75 × 109/L,
• •5. creatinine clearance \< 50 ml/min per modified Cockcroft-Gault equation,
• •6. aspartate aminotransferase or alanine aminotransferase \> 3.0 × upper limit of normal.
• •10. Hypersensitivity to opioids, history of significant adverse reactions to cannabinoids, and allergy or contraindication to any other drugs administered as a part of this investigation.
• •11. Use of an investigational agent within 30 days.